Kaku igaku. The Japanese journal of nuclear medicine最新文献_第4页

[IAEA Nuclear Cardiology Workshop Abstracts]. [国际原子能机构核心脏病研讨会摘要]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.58.S243

引用次数: 0

[The 3rd Japan Nuclear Medicine Society Kinki Branch Meeting]. 第三届日本核医学学会近畿分会会议。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.abm.2135

引用次数: 0

[Winner announcement]. (赢家公告)。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.58.A1

引用次数: 0

[Exploratory Analysis Results from Post-marketing Surveillance Study of Radium-223 in Japanese Patients with Castration-resistant Prostate Cancer and Bone Metastases: Subgroup Analysis by Age]. [日本去势抵抗性前列腺癌和骨转移患者中镭-223上市后监测的探索性分析结果:按年龄亚组分析]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.oa.2105

Makoto Hosono, Hirotsugu Uemura, Yoshiyuki Kakehi, Naoya Masumori, Shunji Takahashi, Yutaka Okayama, Toshiyuki Sunaya, Tomoyo Horio, Seigo Kinuya

{"title":"[Exploratory Analysis Results from Post-marketing Surveillance Study of Radium-223 in Japanese Patients with Castration-resistant Prostate Cancer and Bone Metastases: Subgroup Analysis by Age].","authors":"Makoto Hosono, Hirotsugu Uemura, Yoshiyuki Kakehi, Naoya Masumori, Shunji Takahashi, Yutaka Okayama, Toshiyuki Sunaya, Tomoyo Horio, Seigo Kinuya","doi":"10.18893/kakuigaku.oa.2105","DOIUrl":"https://doi.org/10.18893/kakuigaku.oa.2105","url":null,"abstract":"Objective: To perform an exploratory analysis on the safety and effectiveness of radium-223 (Ra-223) by patient baseline age, using the results of a post-marketing surveillance study of Ra-223 in castration-resistant prostate cancer patients with bone metastasis in Japan.Method: The safety analysis population of 296 patients was stratified into two groups based on age (<75 and ≥ 75 years-old [yo]), and their characteristics, drugrelated treatment-emergent adverse events (TEAEs), and clinical laboratory values were evaluated. Additionally, these endpoints were evaluated in patients aged ≥ 80 yo.Results: There were 148 patients in each of the <75-yo and ≥ 75-yo age groups, and 69 patients in the ≥ 80-yo age group. The characteristics of patients in the <75-yo group were suggestive of more aggressive disease at diagnosis of prostate cancer and a greater proportion of patients had prior chemotherapy compared with patients in the ≥ 75-yo age group. The incidences of overall drugrelated TEAEs and drug-related hematological TEAEs were slightly higher in the <75-yo age group; however, there was little difference in the incidences of drug-related TEAEs leading to drug discontinuation (1.4-4.1%) between patient groups. Changes in total alkaline phosphatase and prostate-specific antigen values were similar in all groups.Conclusions: Ra-223 therapy seemed tolerable regardless of age in real-world practice in Japan. Especially, there were no new safety concerns of Ra-223 in elderly patients.","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"58 1","pages":"91-101"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39514983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The 92nd Japan Nuclear Medicine Society Chubu Regional Association]. [第92届日本核医学学会中部地区协会]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.arm.2134

引用次数: 0

[The 58th Japan Nuclear Medicine Subcommittee Oncology and Immunonuclear Medicine Study Group 40th Japan Nuclear Medicine Subcommittee Respiratory Nuclear Medicine Study Group]. [第58届日本核医学小组委员会肿瘤和免疫核医学研究组第40届日本核医学小组委员会呼吸核医学研究组]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.asm.2139

引用次数: 0

[Special Program Abstracts]. [特别节目摘要]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.58.S69

引用次数: 0

[A Report on Health Resource Use in Internal Radiation Therapy Using ¹⁷⁷Lu-DOTA-TATE]. [177Lu-DOTA-TATE内放射治疗卫生资源利用报告]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.tr.2104

Katsuhiko Kato, Soichi Nakamura, Yoshinori Matoba, Seigo Kinuya

{"title":"[A Report on Health Resource Use in Internal Radiation Therapy Using 177Lu-DOTA-TATE].","authors":"Katsuhiko Kato, Soichi Nakamura, Yoshinori Matoba, Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2104","DOIUrl":"https://doi.org/10.18893/kakuigaku.tr.2104","url":null,"abstract":"Internal radiation therapy using lutetium-177(177Lu)-DOTA-TATE injection will be applied in actual clinical practice soon. However, the NHI medical technical fee for the use of 177Lu-DOTA-TATE injection has not yet been set. The Japanese Society of Nuclear Medicine surveyed health resource use in internal radiation therapy using 177Lu via questionnaires sent to medical institutions that have used 177Lu-DOTA-TATE injection. Results showed that the necessary cost per patient is 1,912,404 JPY, based on the Draft Proposal for Medical Examination Value (Ver. 7.2) of the Japanese Health Insurance Federation for Surgery. 177Lu-DOTA-TATE injection is supposed to be administered 4 times to each patient at 8-week intervals, and the fee per treatment was calculated to be 478,101 JPY. The appropriate NHI medical technical fee is thus considered to be 47,810 points per patient per treatment, which can be claimed 4 times per patient. In addition, it costs 649,030 JPY per patient to take special measures to make the hospital room similar to the radiation therapy room. The cost other than the basic hospitalization fee per day was calculated to be 81,129 JPY. The appropriate additional points for NHI basic hospitalization fee is thus considered to be 8,113 points per patient per day.","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":"58 1","pages":"39-46"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39054541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[IAEA Nuclear Cardiology Workshop Program]. [国际原子能机构核心脏病学研讨会计划]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.58.S235

引用次数: 0

[Long-term Quality Control Test of a ⁶⁸Ge/⁶⁸Ga Generator]. [68Ge/68Ga发电机长期质量控制试验]。

Kaku igaku. The Japanese journal of nuclear medicine Pub Date : 2021-01-01 DOI: 10.18893/kakuigaku.tr.2102

Sho Tomita, Kei Higashikawa, Satoshi Ueno, Yuki Mizuno, Shusaku Tazawa, Yuji Kuge

引用次数: 0